Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l‐asparaginase: an in vitro study
- 31 July 2006
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 134 (5) , 526-531
Abstract
Summary: Thrombosis occurs in 37% of children with acute lymphoblastic leukaemia (ALL) and is related to an l‐asparaginase‐induced acquired antithrombin (AT) deficiency. The incidence dictates the need for anticoagulant prophylaxis. Direct thrombin inhibitors (DTI) are independent of AT for effect and may thus have advantages in this population. The objective of this study was to determine the interaction of an AT deficiency with the anticoagulant effects of a DTI and a low molecular weight heparin (LMWH). Plasma samples from children with ALL were pooled (mean AT 0·53 U/ml). LMWH 0·3 and 0·7 U/ml or melagatran 0·3 and 0·5 μmol/l were added to the pools, then divided and AT was added back to one aliquot. In additional experiments, AT was added to AT immuno‐depleted plasma. Endogenous thrombin generation capacity (ETGC) was assessed by the continuous method. In plasma with LMWH, there was a 66–88% decrease in ETGC in AT‐normalised samples compared with neat. Conversely, no significant difference in ETGC with or without AT added for melagatran was seen. Experiments with AT‐depleted plasma showed no effect of AT level on anticoagulant activity of DTI, but a significant relationship for LMWH. By contrast to LMWH, DTI provides a consistent anticoagulant response independent of AT levels in children with AT deficiency.Keywords
This publication has 32 references indexed in Scilit:
- Argatroban for anticoagulation during cardiopulmonary bypass in an infantPediatric Anesthesia, 2005
- New anticoagulantsBlood, 2005
- Effects of antithrombin and heparin cofactor II levels on anticoagulation with IntimatanThrombosis and Haemostasis, 2005
- The Effects of Argatroban on Thrombin Generation and Hemostatic Activation In VitroAnesthesia & Analgesia, 2004
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee ReplacementNew England Journal of Medicine, 2003
- Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemiaThrombosis and Haemostasis, 2003
- Treatment of Hereditary and Acquired Thrombophilic DisordersSeminars in Thrombosis and Hemostasis, 1999
- Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L‐asparaginaseAmerican Journal of Hematology, 1994